Watson to market cancer drug
From Times Wire Services
Watson Pharmaceuticals Inc. won clearance to sell the first generic version of Pfizer Inc.’s cancer drug Camptosar.
The Food and Drug Administration approved Watson’s generic irinotecan hydrochloride after patents on the brand-name drug expired. Corona-based Watson said it was entitled to 180 days of market exclusivity before the FDA could approve another generic.
